Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-21-059207
Filing Date
2021-04-30
Accepted
2021-04-30 17:14:58
Documents
8
Period of Report
2021-07-13

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm212442-1_def14a.htm DEF 14A 1446498
2 GRAPHIC lg_eagle-4clr.jpg GRAPHIC 25464
3 GRAPHIC sg_scotttarriff-bw.jpg GRAPHIC 7330
4 GRAPHIC tm212442d1-bc_ceopay4c.jpg GRAPHIC 109622
5 GRAPHIC tm212442d1-pc_ceoneos4c.jpg GRAPHIC 148192
6 GRAPHIC tm212442d1-px_annualbw.jpg GRAPHIC 833396
7 GRAPHIC tm212442d1-px_votingbw.jpg GRAPHIC 850998
8 GRAPHIC tm212442d1-tbl_dirskill4c.jpg GRAPHIC 384131
  Complete submission text file 0001104659-21-059207.txt   4691529
Mailing Address 50 TICE BOULEVARD, SUITE 315 WOODCLIFF LAKE NJ 07677
Business Address 50 TICE BOULEVARD, SUITE 315 WOODCLIFF LAKE NJ 07677 201-326-5300
EAGLE PHARMACEUTICALS, INC. (Filer) CIK: 0000827871 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36306 | Film No.: 21879678
SIC: 2834 Pharmaceutical Preparations